Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

AIDS ◽  
2008 ◽  
Vol 22 (15) ◽  
pp. 1979-1991 ◽  
Author(s):  
Hla-Hla Thein ◽  
Qilong Yi ◽  
Gregory J Dore ◽  
Murray D Krahn
2005 ◽  
Vol 192 (6) ◽  
pp. 992-1002 ◽  
Author(s):  
Jürgen K. Rockstroh ◽  
Amanda Mocroft ◽  
Vincent Soriano ◽  
Cristina Tural ◽  
Marcello H. Losso ◽  
...  

2001 ◽  
Vol 12 (3) ◽  
pp. 157-163 ◽  
Author(s):  
Curtis L Cooper ◽  
Andrew D Badley ◽  
Jonathan B Angel

Knowledge pertaining to hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infection is currently incomplete or conflicting. Several points are well studied, however. Plasma HCV RNA levels are higher in matched HIV-infected people than in HIV-seronegative control subjects and are inversely correlated with CD4+T lymphocyte counts. HCV genotype does not appear to influence this value. Co-infected individuals develop histological and clinical features of HCV liver disease more rapidly than HIV-seronegative patients. Co-infected individuals appear to respond to interferon-alpha therapy equally as well as HIV-seronegative HCV-infected adults, but minimal information exists regarding the efficacy and toxicity of combination HCV therapy (interferon-alpha plus ribavirin) in this population. Adverse consequences of highly active antiretroviral therapy in co-infected patients include hepatic toxicity and, in a minority of patients, an 'immune restoration syndrome'. It is unclear whether long term, highly active antiretroviral therapy positively or negatively influences the natural history of HCV infection.


2007 ◽  
Vol 0 (0) ◽  
pp. 070501060544002-??? ◽  
Author(s):  
F. Fabrizi ◽  
B. Takkouche ◽  
G. Lunghi ◽  
V. Dixit ◽  
P. Messa ◽  
...  

2021 ◽  
pp. 172460082110569
Author(s):  
Hongpeng Wang ◽  
Yixiu Liu ◽  
Yanguang Zhao

Background Previous studies have reported that hepatitis C virus infection may increase the risk of thyroid disease and even thyroid cancer, but quantitative assessments of risk were rare and the results were not consistent. The purpose of this study was to evaluate the impact of hepatitis C virus infection on thyroid disease and thyroid cancer, and to provide clues to explore their relationship. Methods A literature retrieval was performed up to August 20, 2021 in the database of PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, and Wang Fang. The risk of hepatitis C virus for thyroid disease or thyroid cancer was expressed with odds ratio (OR) and 95% confidence intervals (CI). Subgroup analysis was used to explore the source of heterogeneity. Eight articles (Five studies published as articles and three as abstracts) were included in this meta-analysis, with a total of 5398 controls and 1925 cases of hepatitis C. Results The results of a meta-analysis found that hepatitis C virus infection was significantly associated with an increased risk of thyroid disease (sum OR = 1.80, 95% CI = 1.54–2.10, P < 0.001, I2 = 74.3%) and thyroid cancer (sum OR = 16.74, 95% CI = 4.78–58.55, P < 0.001, I2 = 0%). Hepatitis C virus infection may increase the risk of thyroid disease and thyroid cancer. Conclusion More work is needed in the future to establish a causal role; however, an awareness of the possibility of increased risk of thyroid disease and thyroid cancer may lead to earlier diagnosis and better outcomes in patients with hepatitis C.


Sign in / Sign up

Export Citation Format

Share Document